Entrada Therapeutics presents Phase 1/2 DMD trial data for ENTR-601-44.
Entrada shared a corporate presentation on its ENTR-601-44 candidate in Duchenne muscular dystrophy, outlining expectations for open-label period completion by end-2026 and multiple dose cohorts with escalating exposure. The presentation contains forward-looking statements about
View filing at SEC.gov →